A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer
出版年份 2022 全文链接
标题
A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer
作者
关键词
-
出版物
Frontiers in Immunology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-11-14
DOI
10.3389/fimmu.2022.1027449
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Copper induces cell death by targeting lipoylated TCA cycle proteins
- (2022) Peter Tsvetkov et al. SCIENCE
- A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma
- (2022) Zilong Bian et al. Genes
- A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma
- (2022) Genhao Zhang et al. Scientific Reports
- Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
- (2022) Haozhen Lv et al. Frontiers in Pharmacology
- A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA
- (2022) Mingyi Yang et al. Frontiers in Immunology
- Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma
- (2022) Yun Chen Frontiers in Genetics
- Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
- (2022) Liuqing Yang et al. Frontiers in Genetics
- Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma
- (2022) Shengxian Xu et al. Frontiers in Genetics
- Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker
- (2022) Chi Zhang et al. Frontiers in Genetics
- Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma
- (2022) Miaorong Xu et al. Frontiers in Oncology
- Cuproptosis-Related Gene – SLC31A1, FDX1 and ATP7B – Polymorphisms are Associated with Risk of Lung Cancer
- (2022) Yuhui Yun et al. Pharmacogenomics & Personalized Medicine
- The inhibitive effects of proteasome inhibitor MG-132 on pterygium fibroblasts in vitro and the potential key regulators involved
- (2021) Dandan Zhao et al. LIFE SCIENCES
- A tandem activation of NLRP3 inflammasome induced by copper oxide nanoparticles and dissolved copper ion in J774A.1 macrophage
- (2021) Xiaoqi Tao et al. JOURNAL OF HAZARDOUS MATERIALS
- The Immune Heterogeneity Between Pulmonary Adenocarcinoma and Squamous Cell Carcinoma: A Comprehensive Analysis Based on lncRNA Model
- (2021) Tao Yan et al. Frontiers in Immunology
- m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer
- (2021) Zuwei Li et al. Journal of Oncology
- Targets for Therapy of Bladder Cancer
- (2020) Christof Seidl SEMINARS IN NUCLEAR MEDICINE
- Thymoquinone suppresses invasion and metastasis in bladder cancer cells by reversing EMT through the Wnt/β-catenin signaling pathway
- (2020) Mengzhao Zhang et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Treatment of muscle‐invasive and advanced bladder cancer in 2020
- (2020) Vaibhav G. Patel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
- (2020) Vitaly Chasov et al. Frontiers in Oncology
- Bladder Cancer
- (2020) Andrew T. Lenis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy
- (2020) Pierre Lelièvre et al. Cancers
- Role of lncRNA LUCAT1 in cancer
- (2020) Ce Xing et al. BIOMEDICINE & PHARMACOTHERAPY
- Wnt signalling pathway in bladder cancer
- (2020) Guanlin Wu et al. CELLULAR SIGNALLING
- HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics
- (2020) Carlla Assis Araujo-Silva et al. International Journal for Parasitology-Drugs and Drug Resistance
- PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells
- (2019) Songtao Cheng et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Tubastatin�A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells
- (2019) Alejandro Urdiciain et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
- (2019) Francesca Finotello et al. Genome Medicine
- The pan‐cancer mutational landscape of the PPAR pathway reveals universal patterns of dysregulated metabolism and interactions with tumor immunity and hypoxia
- (2019) Wai Hoong Chang et al. Annals of the New York Academy of Sciences
- lncRNA TUC338 is a potential diagnostic biomarker for bladder cancer
- (2019) Gang Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- An EMT‐related gene signature for the prognosis of human bladder cancer
- (2019) Rui Cao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- The global burden of urinary bladder cancer: an update
- (2019) Anke Richters et al. WORLD JOURNAL OF UROLOGY
- The classic metal-sensing transcription factor MTF1 promotes myogenesis in response to copper
- (2019) Cristina Tavera-Montañez et al. FASEB JOURNAL
- Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer
- (2019) Changhao Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro
- (2018) Jennifer Bourn et al. Drug Design Development and Therapy
- LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis
- (2018) Jing Quan et al. OncoTargets and Therapy
- Bladder Cancer Survivorship
- (2018) Sumeet K. Bhanvadia Current Urology Reports
- Immunotherapy in Bladder Cancer
- (2016) Monali Vasekar et al. Current Molecular Pharmacology
- Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
- (2014) Paul Geeleher et al. GENOME BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now